Company: TVRD
Filing Date: 2025-02-14
Form Type: 424B3
Source: 0001104659-25-014310
Chunk: 953

Company: Tvardi Therapeutics, Inc.
Filing Date: 2025-02-14
Form: 424B3
Chunk 953
---
 or benefit due to the Company’s current year losses and full valuation allowance. As of September 30, 2024, the Company evaluated all available evidence and concluded that a valuation allowance is still required against its net deferred tax assets because it is more likely than not they will not be realized in the foreseeable future.. 12. Net Loss Per Share Basis and diluted net loss per share attributable to common stockholders was calculated as follows (dollar amounts in thousands):

| ​                                                                         
 ​                                                                         
 Numerator:                                                                | ​ 
 ​ 
 ​ | ​ 
 ​ 
 ​ | For the Nine Months EndedSeptember 30, 
 2024                                   
 ​                                      | ​ |          ​ | ​ | ​ 
 ​ | ​ 
 ​ | 2023 
 ​    | ​ |          ​ | ​ | ​ 
 ​ 
 ​ |
|:--------------------------------------------------------------------------|:--|:--|:---------------------------------------|:--|-----------:|:--|:--|:--|:-----|:--|-----------:|:--|:--|
| Net loss attributable to common stockholders                              | ​ | ​ | ​                                      | $ |    -16,690 | ​ | ​ | ​ | ​    | $ |    -12,996 | ​ | ​ |
| Denominator:                                                              | ​ | ​ | ​                                      | ​ |          ​ | ​ | ​ | ​ | ​    | ​ |          ​ | ​ | ​ |
| Weighted-average common shares outstanding, basic and diluted             | ​ | ​ | ​                                      | ​ | 19,192,595 | ​ | ​ | ​ | ​    | ​ | 19,134,072 | ​ | ​ |
| Net loss per share attributable to common stockholders, basic and diluted | ​ | ​ | ​                                      | $ |      -0.87 | ​ | ​ | ​ | ​    | $ |      -0.68 | ​ | ​ |

The Company’s potentially dilutive securities, which include stock options to purchase common stock and Preferred Stock, have been excluded from the computation of diluted net loss per share as the effect would be anti-dilutive. Therefore, the weighted average number of common shares outstanding used to calculate both basic and diluted net loss per share attributable to common stockholders is the same. The following potentially dilutive securities have been excluded from the calculation of diluted net loss per share due to their anti-dilutive effect:

| ​                                              | ​ | ​ | For the Nine Months EndedSeptember